Analytical Data
-
基因名
PEAK1
- Application
-
别名
FLJ21140; FLJ34483; KIAA2002; NKF3 kinase family member ; PEAK1; PEAK1_HUMAN; pseudopodium enriched atypical kinase; Pseudopodium-enriched atypical kinase 1; SGK269; Sugen kinase 269; Tyrosine-protein kinase SgK269
-
种属
Human
-
表达系统
E. coli
-
标签
GST-tag at N-terminal
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q9H792
-
表达区间
1151-1250 aa
-
氨基酸序列
TPPPLPKKMIIRANTEPISKDLQKSMESSLCVMANPTYDIDPNWDASSAGSSISYELKGLDIESYDSLERPLRKERPVPSAANSISSLTTLSIKDRFSNS
-
分子量
36.63 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
PEAK1, or Pseudopodium-enriched atypical kinase 1, is a member of the Ser/Thr kinase family, primarily involved in regulating cytoskeletal dynamics and cellular signaling pathways. Its significance has been underscored in various biological processes, including cell migration, adhesion, and proliferation. Abnormal expression and activity of PEAK1 have been linked to multiple diseases, particularly cancer, where it is believed to contribute to tumor progression and metastasis. Recent studies have indicated that PEAK1 functions as a key mediator in the signaling pathways activated by extracellular stimuli, thereby influencing cellular responses to the microenvironment. The interest in PEAK1 as a therapeutic target has spurred efforts to produce recombinant PEAK1 protein, enabling detailed investigations into its structure, function, and interactions at the molecular level. By generating and characterizing this recombinant protein, researchers aim to elucidate the precise mechanisms by which PEAK1 influences cellular behavior and to explore its potential as a novel biomarker or therapeutic target in cancer and other diseases. The study of PEAK1 not only enhances our understanding of fundamental cellular processes but also opens new avenues for targeted therapies in oncology, making it a focal point in current biomedical research.
